A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab shares have doubled over the past three months after a string of cancer drug trial wins, marking a high-stakes payoff for the little-known Danish biotech's push to own more of the medicines it develops. The company, long known for licensing its antibody technologies to larger partners, has been shifting toward retaining greater commercial rights to its pipeline, a strategy that carries more risk but also far greater upside when trials succeed. The trial wins validate that bet, giving Genmab stronger negotiating leverage with partners and a clearer path to capturing more of the revenue from its own discoveries. Investors have rewarded the momentum, driving the stock to double in value as sentiment on the company's standalone prospects improves. What to watch next: whether Genmab can convert its trial successes into regulatory approvals and commercial launches, and whether it continues to buy back or renegotiate rights to assets currently controlled by big pharma partners.